Analyst William Pickering of Bernstein maintained a Hold rating on Biogen, with a price target of $155.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
William Pickering has given his Hold rating due to a combination of factors that reflect both positive and cautious elements in Biogen’s recent performance. The company reported strong financial results for the second quarter of 2025, with revenues and EPS significantly surpassing consensus estimates. However, much of this success was attributed to one-time events and timing adjustments, which may not be sustainable in the long term.
Additionally, while Biogen’s Leqembi sales showed encouraging growth, the competitive landscape remains challenging, with competitors like Lilly gaining market share. The company’s pipeline updates, including new studies and potential advancements, offer some promise, but the commercial opportunities remain uncertain. Given these mixed signals, Pickering maintains a Hold rating, suggesting that investors should neither buy nor sell the stock at this time.
In another report released on August 1, Citi also maintained a Hold rating on the stock with a $135.00 price target.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is neutral on the stock.